Suppr超能文献

拉贝洛尔在高血压急症治疗中的应用

[Use of labetalol in the treatment of hypertensive crises].

作者信息

Semplicini A, Pessina A C, Rossi G P, Palatini P, Hlede M, Morandin F, Visonà A, Mazzucato A, Dal Palù C

出版信息

G Ital Cardiol. 1982;12(5):355-8.

PMID:7152187
Abstract

Labetalol, a combined alpha and beta adrenoceptor blocking drug, has been shown to be effective in the treatment of hypertensive crises when given intravenously. It also offers the advantage that treatment can be continued with the oral preparation. The purpose of our study was to evaluate if the administration of an intravenous bolus followed by an iv infusion and subsequently by the oral preparation might increase the efficacy of the drug without reducing its tolerance. Thirteen patients with severe essential hypertension and one with pheochromocytoma were treated during one or more hypertensive crises with Labetalol, 100 mg bolus i.v. injection in two minutes, followed by an intravenous infusion (2-4 mg/min for 60-90 minutes) and, one hour after the end of the infusion, by the oral preparation (200 mg t.i.d.). In 11 subjects with essential hypertension and in the patient with pheochromocytoma a 30% fall in systolic and diastolic blood pressure [from 240 +/- 10/155 +/- 6 mmHg (mean +/- 1 s.e.m.), to 162 +/- 8/111 +/- 6, p less than 0.01] was achieved within five minutes from the beginning of the treatment. Blood pressure remained well controlled thereafter, throughout the infusion period and during the first 24 hours of the oral administration. Heart rate fell simultaneously with the fall in blood pressure. Only in one patient blood pressure was not adequately controlled despite of the bolus and of an infusion at the rate of 4 mg/min for 20 minutes. In another case the fall in pressure caused near-fainting and the infusion was therefore not started. No other side effects were encountered except for transient orthostatic hypotension. We conclude that the administration of a bolus plus infusion of Labetalol is more effective than single or repeated boluses or graded infusions and it is equally well tolerated.

摘要

拉贝洛尔是一种兼具α和β肾上腺素能受体阻滞作用的药物,已证明静脉给药时对治疗高血压危象有效。它还有一个优点,即后续可用口服制剂继续治疗。我们研究的目的是评估静脉推注后接着静脉滴注,随后再给予口服制剂,是否能提高该药的疗效而又不降低其耐受性。13例重度原发性高血压患者和1例嗜铬细胞瘤患者在一次或多次高血压危象期间接受了拉贝洛尔治疗,先在两分钟内静脉推注100mg,接着静脉滴注(2 - 4mg/分钟,持续60 - 90分钟);滴注结束一小时后,给予口服制剂(200mg,每日三次)。11例原发性高血压患者及嗜铬细胞瘤患者在治疗开始后五分钟内,收缩压和舒张压均下降了30%[从240±10/155±6mmHg(均值±1标准误)降至162±8/111±6,p<0.01]。此后在整个滴注期间以及口服给药的头24小时内,血压一直得到良好控制。心率随血压下降同步降低。仅1例患者尽管推注了药物且以4mg/分钟的速度静脉滴注了20分钟,但血压仍未得到充分控制。在另一例中,血压下降导致近乎昏厥,因此未开始滴注。除了短暂的体位性低血压外,未出现其他副作用。我们得出结论,拉贝洛尔推注加滴注的给药方式比单次或重复推注或分级滴注更有效,且耐受性相当。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验